Survival in Patients with Stage IV Noncardia Gastric Cancer - the Influence of DNA Ploidy and Helicobacter Pylori Infection

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2012 Aug 16

PMID 22892134

Citations 13

Authors

John Syrios

Stavros Sougioultzis

Ioannis D Xynos

Nikolaos Kavantzas

Christos Kosmas

George Agrogiannis

John Griniatsos

Ioannis Karavokyros

Emmanouil Pikoulis

Efstratios S Patsouris

Nikolas Tsavaris

Affiliations

Soon will be listed here.

Abstract

Background: Palliative surgery followed by postoperative chemotherapy is a challenging approach in the treatment of stage IV gastric cancer yet patients must be carefully selected on the basis of likely clinical benefit.

Methods: The records of 218 patients with histological diagnosis of gastric adenocarcinoma who underwent palliative surgery followed by postoperative chemotherapy were retrospectively reviewed. Twelve potential prognostic variables including tumour DNA index and serum IgG anti- Helicobacter pylori (HP) antibodies were evaluated for their influence on overall survival by multivariate analysis.

Results: The median survival was 13.25 months [95% Confidence Interval (CI) 12.00, 14.50]. Three factors were found to have an independent effect on survival: performance status (PS) [PS 60-70 vs. 90-100 Hazard Ratio (HR) 1.676; CI 1.171-2.398, p = 0.005], liver metastases (HR 1.745; CI 1.318-2.310, p < 0.001), and DNA Index as assessed by Image cytometry (2.2-3.6 vs. >3.6 HR 3.059; CI 2.185-4.283, p < 0.001 and <2.2 vs. >3.6 HR; 4.207 CI 2.751-6.433 <0.001). HP infection had no statistically significant effect on survival by either univariate or multivariate analysis.

Conclusion: Poor pre-treatment PS, the presence of liver metastasis and high DNA Index were identified factors associated with adverse survival outcome in patients with Stage IV gastric cancer treated with palliative gastrectomy and postoperative chemotherapy. HP infection had no influence on survival of these patients.

Citing Articles

Positive H. pylori status predicts better prognosis of non-cardiac gastric cancer patients: results from cohort study and meta-analysis.

Jia Z, Zheng M, Jiang J, Cao D, Wu Y, Zhang Y BMC Cancer. 2022; 22(1):155.

PMID: 35135494 PMC: 8822753. DOI: 10.1186/s12885-022-09222-y.

Survival of gastric cancer patients based on pathologic and demographic characteristics in Mazandaran between 2007 and 2013.

Nikpour A, Khalilian A, Maleki I, Mohsenipouya H, Yazdani Charati J Gastroenterol Hepatol Bed Bench. 2019; 12(4):315-321.

PMID: 31749920 PMC: 6820842.

Prognostic value of DNA aneuploidy in gastric cancer: a meta-analysis of 3449 cases.

Xu J, Zhu R, Fan L, Ge S, Wei W, Li X BMC Cancer. 2019; 19(1):650.

PMID: 31266459 PMC: 6607593. DOI: 10.1186/s12885-019-5869-9.

Activation of CD3 T cells by Helicobacter pylori DNA vaccines in potential immunotherapy of gastric carcinoma.

Xue L, Mao X, Liu X, Gao H, Chen Y, Dai T Cancer Biol Ther. 2019; 20(6):866-876.

PMID: 30786815 PMC: 6605983. DOI: 10.1080/15384047.2019.1579957.

Clinical Influence of Ploidy and Cancer Stem Cells and Other Parameters in Stage IV Colorectal Cancer.

Polyzos K, Karadima M, Kosma A, Lazaris A, Kavantzas N, Tsavaris N In Vivo. 2018; 33(1):245-249.

PMID: 30587631 PMC: 6364067. DOI: 10.21873/invivo.11467.

References

Gonzalez C, Megraud F, Buissonniere A, Lujan Barroso L, Agudo A, Duell E . Helicobacter pylori infection assessed by ELISA and by immunoblot and noncardia gastric cancer risk in a prospective study: the Eurgast-EPIC project. Ann Oncol. 2011; 23(5):1320-1324. DOI: 10.1093/annonc/mdr384. View

Polk D, Peek Jr R . Helicobacter pylori: gastric cancer and beyond. Nat Rev Cancer. 2010; 10(6):403-14. PMC: 2957472. DOI: 10.1038/nrc2857. View

Moon Y, Rha S, Jeung H, Kim C, Hong M, Chang H . Outcomes of multiple salvage chemotherapy for advanced gastric cancer: implications for clinical practice and trial design. Cancer Chemother Pharmacol. 2010; 66(4):797-805. DOI: 10.1007/s00280-010-1295-z. View

Hartgrink H, Jansen E, van Grieken N, van de Velde C . Gastric cancer. Lancet. 2009; 374(9688):477-90. PMC: 4613761. DOI: 10.1016/S0140-6736(09)60617-6. View

Qiu H, Zhang L, Keshari R, Wang G, Zhou Z, Xu D . Relationship between H.Pylori infection and clinicopathological features and prognosis of gastric cancer. BMC Cancer. 2010; 10:374. PMC: 2914705. DOI: 10.1186/1471-2407-10-374. View

Baba H, Korenaga D, Okamura T, Saito A, Watanabe A, Sugimachi K . Prognostic significance of DNA content with special reference to age in gastric cancer. Cancer. 1989; 63(9):1768-72. DOI: 10.1002/1097-0142(19900501)63:9<1768::aid-cncr2820630919>3.0.co;2-g. View

Sun Z, Wang S . [Study on factors influencing survival in patients with advanced gastric carcinoma after resection by Cox's proportional hazard model]. Zhonghua Zhong Liu Za Zhi. 1996; 18(6):433-5. View

Kang S, Han J, Ahn M, Lee H, Jeong S, Park J . Helicobacter pylori infection as an independent prognostic factor for locally advanced gastric cancer patients treated with adjuvant chemotherapy after curative resection. Int J Cancer. 2011; 130(4):948-58. DOI: 10.1002/ijc.26081. View

Kim J, Ryoo B, Park Y, Kim B, Kim T, Im Y . Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy. Cancer Chemother Pharmacol. 2007; 61(2):301-7. DOI: 10.1007/s00280-007-0476-x. View

10.

Danova M, Riccardi A, Mazzini G, Wilson G, Dionigi P, Brugnatelli S . Flow cytometric analysis of paraffin-embedded material in human gastric cancer. Anal Quant Cytol Histol. 1988; 10(3):200-6. View

11.

Chau I, Norman A, Cunningham D, Waters J, Oates J, Ross P . Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol. 2004; 22(12):2395-403. DOI: 10.1200/JCO.2004.08.154. View

12.

Mitchell H, English D, Elliott F, Gengos M, Barrett J, Giles G . Immunoblotting using multiple antigens is essential to demonstrate the true risk of Helicobacter pylori infection for gastric cancer. Aliment Pharmacol Ther. 2008; 28(7):903-10. DOI: 10.1111/j.1365-2036.2008.03792.x. View

13.

Tsavaris N, Kosmas C, Kopterides P, Tsikalakis D, Skopelitis H, Sakelaridi F . Retinol-binding protein, acute phase reactants and Helicobacter pylori infection in patients with gastric adenocarcinoma. World J Gastroenterol. 2006; 11(45):7174-8. PMC: 4725071. DOI: 10.3748/wjg.v11.i45.7174. View

14.

Lee J, Lim T, Uhm J, Park K, Park S, Lee S . Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma. Ann Oncol. 2007; 18(5):886-91. DOI: 10.1093/annonc/mdl501. View

15.

Hobsley M, Tovey F, Holton J . Helicobacter pylori and gastric cancer: neither friend nor foe. Gastroenterology. 2007; 132(5):2076. DOI: 10.1053/j.gastro.2007.03.088. View

16.

Correa P, Piazuelo M . Helicobacter pylori Infection and Gastric Adenocarcinoma. US Gastroenterol Hepatol Rev. 2011; 7(1):59-64. PMC: 3158605. View

17.

Jeung H, Rha S, Jang W, Noh S, Chung H . Treatment of advanced gastric cancer by palliative gastrectomy, cytoreductive therapy and postoperative intraperitoneal chemotherapy. Br J Surg. 2002; 89(4):460-6. DOI: 10.1046/j.0007-1323.2001.02048.x. View

18.

Meimarakis G, Winter H, Assmann I, Kopp R, Lehn N, Kist M . Helicobacter pylori as a prognostic indicator after curative resection of gastric carcinoma: a prospective study. Lancet Oncol. 2006; 7(3):211-22. DOI: 10.1016/S1470-2045(06)70586-1. View

19.

Kanagavel D, Pokataev I, Fedyanin M, Tryakin A, Bazin I, Narimanov M . A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy. Ann Oncol. 2010; 21(9):1779-1785. DOI: 10.1093/annonc/mdq032. View

20.

Belien J, Buffart T, Gill A, Broeckaert M, Quirke P, Meijer G . Gross genomic damage measured by DNA image cytometry independently predicts gastric cancer patient survival. Br J Cancer. 2009; 101(6):1011-8. PMC: 2743350. DOI: 10.1038/sj.bjc.6605266. View